Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mgnium is an oral dietary supplement developed by Bion Therapeutics. It is formulated as a tablet containing a combination of magnesium oxide (300 mg) and magnesium gluconate (400 mg), providing 200 mg of elemental magnesium. Magnesium is an essential mineral that plays a critical role in over 300 enzymatic reactions, energy production, and maintaining normal nerve and muscle function. At the neurocellular level, magnesium acts as a voltage-dependent blocker of the N-methyl-D-aspartate (NMDA) receptor, thereby regulating neuronal excitability and preventing excitotoxicity. It also acts as a positive allosteric modulator of GABA-A receptors, promoting relaxation and reducing stress. Mgnium is primarily indicated for supporting bone and teeth health, reducing tiredness and fatigue, and maintaining normal psychological and nervous system function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mgnium.